Latest Boehringer Ingelheim Stories
Boehringer Ingelheim agrees to pay $650 Million to compensate the nearly 4,000 individuals who allege they were injured as a result of Pradaxa usage. CHICAGO, May 29, 2014 /PRNewswire/
Seth A. Katz and Burg Simpson Eldredge Hersh & Jardine, P.C. are pleased to announce that earlier today Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S.
BEDFORD, Ohio, May 28, 2014 /PRNewswire/ -- Ben Venue Laboratories. Inc.
European Commission approves third product from the Boehringer Ingelheim and Lilly Diabetes alliance RIDGEFIELD, Conn.
-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of
- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF)
- Growing in low tufty patches.